Publications en collaboration avec des chercheurs de University of Paris-Saclay (13)

2024

  1. A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer

    Lung Cancer, Vol. 197

  2. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

    ESMO Open, Vol. 9, Núm. 6

2020

  1. Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) – A decision-making analysis amongst European lung cancer experts

    Lung Cancer, Vol. 146, pp. 6-11

  2. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer

    Lung Cancer, Vol. 142, pp. 63-69

  3. Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts

    Radiotherapy and Oncology, Vol. 149, pp. 84-88

2019

  1. Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts

    Radiotherapy and Oncology, Vol. 135, pp. 74-77

  2. Erratum to “Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts” [Radiother. Oncol. 135 (2019) 74–77](S0167814019300775)(10.1016/j.radonc.2019.02.010)

    Radiotherapy and Oncology

  3. Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC

    Journal of Thoracic Oncology, Vol. 14, Núm. 10, pp. 1828-1838

  4. Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts

    Radiotherapy and Oncology, Vol. 133, pp. 163-166

  5. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer

    European Journal of Cancer, Vol. 108, pp. 120-128

2018

  1. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer

    JAMA Oncology, Vol. 4, Núm. 3, pp. 351-357

  2. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

    The Lancet Respiratory Medicine, Vol. 6, Núm. 10, pp. 771-781

2017

  1. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC

    Journal of Thoracic Oncology, Vol. 12, Núm. 2, pp. 194-207